iNK-CD64/16A cells: a promising approach for ADCC?

ABSTRACT

Introduction: ADCC by natural killer (NK) cells is a key mechanism for several clinically successful tumor-targeting therapeutic antibodies. Most patients, however, have limited responses to this therapy and/or develop resistance. NK cells exclusively recognize IgG by their low-affinity FcγR CD16A.

Areas covered: We describe in this editorial a novel recombinant FcγR that consists of CD64, the only high affinity IgG receptor, and the transmembrane and cytoplasmic regions of CD16A, a potent activating receptor. CD64/16A was expressed in engineered iPSCs that were differentiated into NK cells (referred to as iNK cells).

Expert opinion: iNK-CD64/16A cells in combination with therapeutic antibodies provide a universal tumor antigen targeting approach and potential off-the-shelf cell therapy to treat various malignancies.

KEYWORDS:

• Natural killer cells
• antibody
• Fc receptor
• mAb therapy
• cell therapy
• cancer
• stem cell

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

One of the reviewers on this paper has patents/royalties for CAR T cell therapies for multiple myeloma. In addition, this same reviewer reports consulting for Celgene, Precision Biosciences, and Fate Therapeutics. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was funded by the National Institutes of Health, including R01CA203348 and R21AI125729, and the Minnesota Ovarian Cancer Alliance.